Intermittent Selumetinib for Uveal Melanoma

Learn more about:
Related Clinical Trial
Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 Prospective Registration Of Patient Data and Quality of Life in Eye Melanoma Patients Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma) The Role of Genetic Mutations and of Circulating mRNAs in Uveal Melanoma A Study of Concurrent Stereotactic Body Radiotherapy With Ipi and Nivo in Metastatic Uveal Melanoma Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma Managed Access Program Supporting Patient Access to Tebentafusp Efficacy of Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors Early Integration of Supportive Care Into Standard Oncology Care for Metastatic Uveal Melanoma Patients Defactinib (VS-6063) Combined With VS-6766 in Patients With Metastatic Uveal Melanoma Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma A Prospective Natural History Study in Uveal Melanoma Uveal Melanoma and Brachytheraphy: Long-term Outcomes. A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas Study to Evaluate the Safety of IMM-01 in Patients With Advanced Solid Tumours Isolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastases Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME) Phase 2 Trial of AU-011 Via Suprachoroidal Administration With a Dose Escalation and Randomized, Masked Dose Expansion Designed to Evaluate Safety and Efficacy of AU-011 in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery A Study of PLX2853 in Advanced Malignancies. Combined PET/CT Imaging for the Early Detection of Ocular Melanoma Metastasis Compared to CT Scanning Alone A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) Genetic Predictors of Efficiency and Safety of ICIs in Patients With Different Malignancies (ICIPRESIST-0519) Treatment Of Radiation Retinopathy Trial Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin Study in Subjects With Small Primary Choroidal Melanoma Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination Trial of AEB071 in Combination With BYL719 in Patients With Melanoma Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF Vorinostat in Treating Patients With Metastatic Melanoma of the Eye Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver Metastases 5 Year Registry Study to Track Clinical Application of DecisionDx-UM Assay Results and Associated Patient Outcomes Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Uveal Melanoma Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma Pembrolizumab in Treating Patients With Advanced Uveal Melanoma Vascular Response to Brachytherapy Using Functional OCT Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma Endoresection of the Tumor Scar or Transpupillary Thermotherapy for the Treatment of Large Uveal Melanomas (Endoresection-Laser) Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma Tilting of Radioactive Plaques After Initial Accurate Placement for Treatment of Uveal Melanoma A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER) Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma New Biopsy Technique for Uveal Melanoma Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients Influence of Oral Treatment With Citicoline for the Prevention of Radiation Optic Neuropathy in Patients Treated for Uveal Melanomas With Proton Beam Therapy Intermittent Selumetinib for Uveal Melanoma Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma. Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Candidate to Complete Resection (ct DNA R0) Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients Study of the Activity of PD-1 Inhibitors in Metastatic Uveal Melanoma A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma Vorinostat in Patients With Class 2 High Risk Uveal Melanoma Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases A Phase II Study of BVD-523 in Metastatic Uveal Melanoma Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma Treatment With Intravitreal Avastin for Large Uveal Melanomas

Brief Title

Intermittent Selumetinib for Uveal Melanoma

Official Title

Multi-Center Phase Ib Study of Intermittent Dosing of the MEK Inhibitor, Selumetinib, in Patients With Advanced Uveal Melanoma Not Previously Treated With a MEK Inhibitor

Brief Summary

      The purpose of this study is to find out what effects, good and/or bad, intermittent dosing
      of the drug Selumetinib will have on subjects with uveal melanoma. Selumetinib is a drug that
      blocks (or turns off) methyl ethyl ketone (MEK), a protein activated in some uveal melanoma
      cells. Selumetinib is a MEK inhibitor. Blocking MEK may stop the cancer from growing.

Detailed Description

      Uveal melanoma (UM) is the most common primary intraocular malignancy in adults, and arises
      from melanocytes within the choroid plexus of the eye. The development of metastasis is
      common and occurs in approximately 50% of patients with posterior UM within 15 years of
      initial diagnosis and treatment. As no effective systemic therapy has yet been identified for
      this disease, outcomes for metastatic UM are poor with a median survival of 12 months.

      There is no FDA approved therapy for patients with advanced UM. Studies have shown that
      inhibition of the Mitogen-activated protein kinase (MAPK) pathway with the MEK inhibitor
      selumetinib (hyd-sulfate AZD6244) is an effective therapy for uveal melanoma but despite this
      treatment, cures are not achieved. Although drugs such as selumetinib have been studied when
      patients take the treatment every day, research has shown that in some cases, it may be
      better to use the treatment on an intermittent schedule. Such a strategy may reduce the side
      effects, allow higher doses of the drug to be used, more completely block the MAPK pathway,
      and prevent the development of drug resistance mechanisms within the tumor.

Study Phase

Phase 1

Study Type


Primary Outcome

Maximum Tolerated Dose (MTD) of intermittent selumetinib

Secondary Outcome

 Number of adverse events (AEs)


Uveal Melanoma



Study Arms / Comparison Groups

Description:  Subjects will receive selumetinib (hyd-sulfate AZD6244) orally twice a day for three days followed by four days off in four week cycles starting at a dose of 125mg. The doses to be studied on a 3 day on, 4 day off schedule are 100mg, 125mg, 150mg, 175mg, 200mg and 225mg as per the time to event continual reassessment (TITE-CRM) design.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

February 28, 2017

Completion Date

September 2022

Primary Completion Date

September 2022

Eligibility Criteria

        Inclusion Criteria:

          -  Histopathologically confirmed diagnosis of metastatic or unresectable uveal melanoma.
             Note - Documentation of mutation status for uveal melanoma will not be required
             prospectively given the high rate of GNAQ/11 mutations (>90%) in this population

          -  Able to provide informed consent prior to initiation of study

          -  Age ≥ 18 years old

          -  Measurable indicator lesion by RECIST v1.1

          -  Patients must have measurable disease, defined as at least one lesion that can be
             accurately measured in at least one dimension (longest diameter to be recorded for
             non-nodal lesions and short axis for nodal lesions) as ≥20 mm with conventional
             techniques or as ≥10 mm with spiral CT scan, MRI, or calipers by clinical exam.

          -  Karnofsky Performance Status ≥ 60% or Eastern Cooperative Oncology Group (ECOG) ≤2

          -  Ability to take oral medications

          -  All clinically significant toxicities from prior therapy must be ≤ grade 1 (with the
             exception of alopecia)

          -  Organ and marrow function and laboratory values as follows:

               -  Adequate marrow function

               -  absolute neutrophil count (ANC) >1500 cells/mm3

               -  platelet count >100,000/mm3

               -  hemoglobin >9.0g/dL

          -  Adequate hepatic function

               -  Angiotensin Sensitivity Test/alternative (AST/ALT)<2.5x upper limit of normal if
                  no documented liver disease or <5x upper limit of normal if documented liver

               -  Total bilirubin <1.5X upper limit of normal unless known diagnosis of Gilbert's

               -  Alkaline phosphatase <2.5x upper limit of normal if no documented liver disease
                  or <6x upper limit of normal if documented liver or bone disease

               -  Creatinine clearance ≥60 mL/min/1.73 m2 for patients with creatinine levels above
                  institutional normal.

          -  Negative pregnancy test (serum or urine) for women of child bearing potential

          -  The effects of selumetinib on the developing human fetus are unknown. For this reason,
             women of child-bearing potential and men must agree to use adequate contraception
             (hormonal or barrier method of birth control; abstinence) prior to study entry and for
             the duration of study participation and 4 weeks after study discontinuation. Should a
             woman become pregnant or suspect she is pregnant while she or her partner is
             participating in this study, she should inform her treating physician immediately. Men
             treated or enrolled on this protocol must also agree to use adequate contraception
             prior to the study, for the duration of study participation, and 3 months after
             completion of selumetinib administration.

        Exclusion Criteria:

          -  Patients who have had chemotherapy or immunotherapy within 4 weeks or radiation
             therapy within 2 weeks prior to entering the study or those who have not recovered
             from adverse events due to agents administered more than 4 weeks earlier.

          -  Patients who are receiving any other investigational agents concurrently. Palliative
             radiation therapy will be allowed as long as the patient meets all other eligibility

          -  Have had recent major surgery within a minimum 4 weeks prior to starting study
             treatment, with the exception of surgical placement for vascular access.

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to selumetinib

          -  Every effort must be made to avoid the use of a concomitant medication that can
             prolong the corrected QT (QTc) interval while receiving selumetinib (hyd-sulfate
             AZD6244). If the patient cannot discontinue medications that prolong QTc interval
             while receiving selumetinib, close cardiac monitoring should be performed.

          -  Patients with QTc interval >450 msecs or other factors that increase the risk of QTc
             prolongation or arrhythmic events (ex. Heart failure, hypokalemia, family history of
             long QT syndrome) including heart failure that meets New York Heart Association (NYHA)
             class III and IV definitions (see Appendix A) are excluded.

          -  Prior or current cardiomyopathy including but not limited to the following: known
             hypertrophic cardiomyopathy, known arrhythmogenic right ventricular cardiomyopathy,
             previous moderate or severe impairment of left ventricular systolic function (LVEF
             <45% on echocardiography or equivalent on MuGA) even if full recovery has occurred.

          -  Atrial fibrillation with a ventricular rate >100 bpm on ECG at rest

          -  Baseline Left ventricular ejection fraction (LVEF) below the LLN or <55% measured by
             echocardiography or institution's lower limit of normal (LLN) for MUGA

          -  Severe valvular heart disease

          -  Uncontrolled Angina - Canadian Cardiovascular Society grade II-IV despite medical

          -  Acute coronary syndrome within 6 months prior to starting treatment

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  Pregnant women are excluded from this study because selumetinib may be teratogenic or
             have abortifacient effects. Because there is an unknown but potential risk for adverse
             events in nursing infants secondary to treatment of the mother with selumetinib,
             breastfeeding should be discontinued if the mother is treated with selumetinib.

          -  HIV positive patients on combination antiretroviral therapy are ineligible because of
             the potential for pharmacokinetic interactions with selumetinib.

          -  Prior treatment with a MEK, Ras or Raf inhibitor

          -  History of current evidence/risk of retinal vein occlusion (RVO) or retinal pigment
             epithelial detachment (RPED) in the eye unaffected by uveal melanoma; intraocular
             pressure (IOP) >21mmgHG or uncontrolled glaucoma

          -  History of interstitial lung disease or pneumonitis

          -  Patients with known Hepatitis B or C

          -  Refractory nausea and vomiting, active gastrointestinal disease (e.g. inflammatory
             bowel disease), or significant bowel resection that would preclude adequate absorption

          -  Patients taking vitamin E supplements while on study

          -  Have known or suspected brain metastases or spinal cord compression, unless the
             condition has been asymptomatic, has been treated with surgery and / or radiation, and
             has been stable for at least 4 weeks prior to the first dose of study medication

          -  Any unresolved toxicity ≥ CTCAE Grade 2 from previous anti-cancer therapy, except for

          -  Have evidence of any other significant clinical disorder or laboratory finding that,
             as judged by the investigator, makes it undesirable for the patient to participate in
             the study.

          -  Patients being actively treated for a secondary malignancy




18 Years - N/A

Accepts Healthy Volunteers



Richard Carvajal, MD, , 

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID


Responsible Party


Study Sponsor

Richard D. Carvajal



Study Sponsor

Richard Carvajal, MD, Principal Investigator, Columbia University

Verification Date

June 2022